Marinus Pharmaceuticals, Inc. provided revenue guidance for the fiscal year 2022. For the period, the company expects BARDA revenues in the range of $7 million to $10 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 USD | +1.50% | -8.78% | -87.58% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.58% | 74.16M | |
+29.98% | 682B | |
+31.61% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.55% | 240B | |
+9.37% | 209B | |
-8.83% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022